Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes. 2023

Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, Suzhou, China.

BACKGROUND Inflammatory bowel disease (IBD) was associated with elevated risk of cardiometabolic diseases in observational studies. We aimed to evaluate the observational and genetic associations of Crohn's disease (CD) and ulcerative colitis (UC) with multiple cardiometabolic outcomes. METHODS Our phenotypic and genetic association analyses included more than 400 000 participants who were free of major cardiovascular disease and diabetes at recruitment (2006-2010) and were followed up until December 2019 based on the UK Biobank. For the Mendelian randomization (MR) analyses, 415 and 273 single nucleotide polymorphisms associated with CD and UC, respectively, were selected as genetic instruments. Summary-level data on individual cardiometabolic outcomes were obtained from 4 different genome-wide association studies with a total of 2 248 842 participants. RESULTS In the multivariable-adjusted observational analyses, CD was associated with higher risks of heart failure (hazard ratio [HR], 1.72; 95% confidence interval, 1.22-2.42) and type 2 diabetes (HR, 2.11; 95% confidence interval, 1.67-2.67) but not with myocardial infarction or ischemic stroke. UC was related to increased risks of all the assessed cardiometabolic diseases (HRs ranged from 1.29 for myocardial infarction to 1.76 for type 2 diabetes). Conversely, neither the genetic risk score for CD nor that for UC was associated with higher risk of developing cardiometabolic diseases. In 2-sample MR analyses, genetically determined CD and UC were not associated with any of the assessed cardiometabolic diseases (all P values >.05). CONCLUSIONS Despite confirming the observational associations, our study does not support a causal association between IBD and elevated risk of cardiometabolic diseases.

UI MeSH Term Description Entries

Related Publications

Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
March 2021, Gastroenterologia y hepatologia,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
December 2022, The American journal of medicine,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
April 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
January 2022, Obesity reviews : an official journal of the International Association for the Study of Obesity,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
September 2022, Materia socio-medica,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
January 2022, PloS one,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
December 2019, Presse medicale (Paris, France : 1983),
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
January 2023, Crohn's & colitis 360,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
October 2022, Diabetic medicine : a journal of the British Diabetic Association,
Zhengbao Zhu, and Yiming Jia, and Fu-Rong Li, and Yang Li, and Li-Hua Chen, and Huan-Huan Yang, and Daoxia Guo, and Lulu Sun, and Mengyao Shi, and Tao Wang, and Thomas E Rohan, and Qibin Qi, and Li-Qiang Qin, and Yonghong Zhang, and Guo-Chong Chen
March 2007, Journal of managed care pharmacy : JMCP,
Copied contents to your clipboard!